Contact this trialFirst, we need to learn more about you.
Kadcyla + Neratinib for Breast Cancer
Recruiting3 awardsPhase 2
Toronto, Ontario
This trial is for patients with early-stage HER2+ breast cancer who still have small amounts of cancer after initial treatments. They will take a drug called neratinib along with their usual treatment. Neratinib works by blocking signals that help cancer cells grow. The study aims to see if this combination improves patient outcomes.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service